HK1217692A1 - 作為鈉通道調節劑的醯胺 - Google Patents
作為鈉通道調節劑的醯胺Info
- Publication number
- HK1217692A1 HK1217692A1 HK16105502.2A HK16105502A HK1217692A1 HK 1217692 A1 HK1217692 A1 HK 1217692A1 HK 16105502 A HK16105502 A HK 16105502A HK 1217692 A1 HK1217692 A1 HK 1217692A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- modulators
- amides
- sodium channels
- channels
- sodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759062P | 2013-01-31 | 2013-01-31 | |
PCT/US2014/013667 WO2014120820A1 (en) | 2013-01-31 | 2014-01-29 | Amides as modulators of sodium channels |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1217692A1 true HK1217692A1 (zh) | 2017-01-20 |
Family
ID=50114569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16105502.2A HK1217692A1 (zh) | 2013-01-31 | 2016-05-13 | 作為鈉通道調節劑的醯胺 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9108903B2 (zh) |
EP (1) | EP2951155B1 (zh) |
JP (1) | JP6346622B2 (zh) |
KR (1) | KR102226588B1 (zh) |
CN (1) | CN104968647B (zh) |
AR (1) | AR094668A1 (zh) |
AU (1) | AU2014212431B2 (zh) |
BR (1) | BR112015018284B1 (zh) |
CA (1) | CA2898653C (zh) |
HK (1) | HK1217692A1 (zh) |
IL (1) | IL240196B (zh) |
MX (1) | MX359882B (zh) |
RU (1) | RU2658920C2 (zh) |
SG (1) | SG11201505954RA (zh) |
TW (1) | TWI659945B (zh) |
WO (1) | WO2014120820A1 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3239134T (pt) | 2013-01-31 | 2021-01-28 | Vertex Pharma | Piridona amidas como moduladores dos canais de sódio |
ES2620379T3 (es) | 2013-01-31 | 2017-06-28 | Vertex Pharmaceuticals Inc. | Quinolina y quinoxalina amidas como moduladores de canales de sodio |
RU2680401C2 (ru) | 2013-07-19 | 2019-02-21 | Вертекс Фармасьютикалз Инкорпорейтед | Сульфонамиды в качестве модуляторов натриевых каналов |
GEP20217223B (en) | 2013-12-13 | 2021-02-10 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
CA3063901A1 (en) | 2017-05-16 | 2018-11-22 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
TW201920081A (zh) | 2017-07-11 | 2019-06-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑的羧醯胺 |
CN111918650A (zh) | 2018-02-12 | 2020-11-10 | 沃泰克斯药物股份有限公司 | 治疗疼痛的方法 |
TWI784207B (zh) | 2018-11-02 | 2022-11-21 | 美商默沙東有限責任公司 | 作為nav1.8 抑制劑之2-胺基-n-雜芳基-菸鹼醯胺 |
BR112021012909A2 (pt) * | 2019-01-04 | 2021-09-14 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de 6-oxo-1,6-di-hidropiridazina, método de preparação do mesmo e uso médico do mesmo |
US20230062053A1 (en) | 2019-01-10 | 2023-03-02 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
CN112479996B (zh) * | 2019-09-12 | 2023-05-26 | 上海济煜医药科技有限公司 | 吡啶氮氧化合物及其制备方法和用途 |
CA3164134A1 (en) * | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
EP4168393A1 (en) | 2020-06-17 | 2023-04-26 | Merck Sharp & Dohme LLC | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
CN114031518B (zh) * | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
CN112225695B (zh) * | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
CA3217565A1 (en) | 2021-05-07 | 2022-11-10 | Ashok Arasappan | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
UY39800A (es) | 2021-06-04 | 2023-01-31 | Vertex Pharma | N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio |
AU2022286438A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
AU2022286511A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
KR20240031299A (ko) | 2021-06-04 | 2024-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법 |
EP4347032A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
AU2022285758A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
WO2023205778A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2511231A (en) * | 1949-03-26 | 1950-06-13 | Eastman Kodak Co | 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography |
CA2648202A1 (en) | 2006-04-11 | 2007-10-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
US8389734B2 (en) * | 2007-10-11 | 2013-03-05 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
EP2212290B1 (en) * | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
CN105254557A (zh) * | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
-
2014
- 2014-01-29 AR ARP140100282A patent/AR094668A1/es unknown
- 2014-01-29 BR BR112015018284-4A patent/BR112015018284B1/pt active IP Right Grant
- 2014-01-29 US US14/167,741 patent/US9108903B2/en active Active
- 2014-01-29 TW TW103103690A patent/TWI659945B/zh active
- 2014-01-29 WO PCT/US2014/013667 patent/WO2014120820A1/en active Application Filing
- 2014-01-29 RU RU2015136779A patent/RU2658920C2/ru active
- 2014-01-29 CA CA2898653A patent/CA2898653C/en active Active
- 2014-01-29 AU AU2014212431A patent/AU2014212431B2/en active Active
- 2014-01-29 SG SG11201505954RA patent/SG11201505954RA/en unknown
- 2014-01-29 MX MX2015009591A patent/MX359882B/es active IP Right Grant
- 2014-01-29 KR KR1020157023600A patent/KR102226588B1/ko active IP Right Grant
- 2014-01-29 CN CN201480006878.4A patent/CN104968647B/zh active Active
- 2014-01-29 EP EP14704981.1A patent/EP2951155B1/en active Active
- 2014-01-29 JP JP2015556113A patent/JP6346622B2/ja active Active
-
2015
- 2015-07-27 US US14/809,841 patent/US9421196B2/en active Active
- 2015-07-28 IL IL240196A patent/IL240196B/en active IP Right Grant
-
2016
- 2016-05-13 HK HK16105502.2A patent/HK1217692A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US9108903B2 (en) | 2015-08-18 |
JP2016508500A (ja) | 2016-03-22 |
KR102226588B1 (ko) | 2021-03-11 |
AU2014212431A1 (en) | 2015-08-06 |
EP2951155A1 (en) | 2015-12-09 |
CN104968647B (zh) | 2018-01-26 |
IL240196B (en) | 2019-08-29 |
EP2951155B1 (en) | 2019-06-19 |
WO2014120820A1 (en) | 2014-08-07 |
MX359882B (es) | 2018-10-15 |
TW201443005A (zh) | 2014-11-16 |
CN104968647A (zh) | 2015-10-07 |
WO2014120820A9 (en) | 2015-07-02 |
AR094668A1 (es) | 2015-08-19 |
AU2014212431B2 (en) | 2018-04-05 |
TWI659945B (zh) | 2019-05-21 |
US20150328196A1 (en) | 2015-11-19 |
CA2898653C (en) | 2021-09-28 |
US20140221435A1 (en) | 2014-08-07 |
RU2658920C2 (ru) | 2018-06-26 |
NZ710293A (en) | 2020-09-25 |
RU2015136779A (ru) | 2017-03-07 |
JP6346622B2 (ja) | 2018-06-20 |
US9421196B2 (en) | 2016-08-23 |
BR112015018284A2 (pt) | 2017-07-18 |
MX2015009591A (es) | 2016-04-15 |
KR20150118964A (ko) | 2015-10-23 |
CA2898653A1 (en) | 2014-08-07 |
SG11201505954RA (en) | 2015-08-28 |
IL240196A0 (en) | 2015-09-24 |
BR112015018284B1 (pt) | 2023-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244269A1 (zh) | 作爲鈉通道調節劑的吡啶酮酰胺 | |
HRP20181563T1 (hr) | Predlijekovi piridonskih amida korisni kao modulatori natrijevih kanala | |
HK1217692A1 (zh) | 作為鈉通道調節劑的醯胺 | |
HK1223604A1 (zh) | 用作鈉通道調節劑的磺醯胺類 | |
HRP20182004T1 (hr) | Tetrahidropiridopirazini modulatori gpr6 | |
HK1225638A1 (zh) | 補體因子b的調節劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM | Amended specification (according sect 146 of patent law) |
Free format text: CORRECTION OF NAME OF APPLICANT FROM "VERTEX PHARMACEUTICAL Effective date: 20200513 |